Pacific Edge
Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and through distributors in other regions.
Short position
Pacific Edge (ASX:PEB) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,063,942 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. PEB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PEB community
Research Threads
Bull, bear, catalyst, and news-reaction posts tied directly to PEB.
Start the first PEB research thread
Anchor the conversation with a thesis, a catalyst, or a question worth debating.